| Literature DB >> 30763378 |
Eva Van Ginderdeuren1,2, Jean Bassett1, Colleen Hanrahan3, Lillian Mutunga1, Annelies Van Rie2.
Abstract
BACKGROUND: Isoniazid preventive therapy (IPT) is a key component of TB/HIV control, but few countries achieve high IPT coverage.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30763378 PMCID: PMC6375590 DOI: 10.1371/journal.pone.0212035
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
IPT and TST uptake during a 3-month period before and 5 months after an intervention consisting of training and a 2-month mentored implementation.
| Clinic | Average monthly number of new HIV diag-noses | IPT strategy pre-intervention | IPT strategy identified through participatory process | TST placements | Average monthly proportion of IPT initiations | ||||
|---|---|---|---|---|---|---|---|---|---|
| TST screening | IPT eligi-bility | TST screening | IPT eligi-bility | Before inter-vention | After inter-vention | Before inter-vention | After inter-vention | ||
| 68 | No | All PLWH emphasis on pregnant women | Yes | All PLWH | 0% | 0% | 34% | 37% | |
| 38 | No | All PLWH emphasis on pregnant women | No | All PLWH | NA | NA | 6% | 36% | |
| 208 | No | All PLWH emphasis on pregnant women | Yes | All PLWH | 0% | 0.5% | 0.7% | 3.0% | |
*Routine registers collected information on IPT initiation in all people newly diagnosed with HIV (clinic 1 and 2) or in all clients receiving HIV care (clinic 3).
Fig 1Flowchart of patients included in review.
Uni- and multivariate analysis of patient-level factors associated with IPT initiation among eligible patients.
| IPT started | IPT not started | OR (95% CI) | aOR (95% CI) | ||
|---|---|---|---|---|---|
| Gender | Female | 52 (68%) | 575 (68%) | 1.03 (0.63–1.74) | |
| Male | 24 (32%) | 274 (32%) | |||
| Age in years (median (IQR)) | 34 (31–43.25) | 39 (32–46) | 0.96 (0.94–0.99) | ||
| Timing of HIV diagnosis compared to IPT eligibility assessment | <90 days | 19 (25%) | 101 (12%) | 2.47 (1.38–4.25) | 3.65 (1.73–7.41) |
| ≥90 days | 57 (75%) | 748 (88%) | |||
| ART status at time of IPT eligibility assessment | On ART | 71 (93%) | 743 (87%) | 2.03 (0.88–5.87) | 9.44 (3.05–36.17) |
| Not on ART | 5 (7%) | 106 (12%) | |||
| Pregnancy status | Pregnant | 13 (17%) | 11 (1%) | 15.72 (6.77–37.20) | 18.62 (6.99–53.46) |
| Not pregnant | 63 (83%) | 838 (99%) | |||
| HIV viral load | Suppressed (<50 copies/ml) | 28 (56%) | 353 (51%) | 1.20 (0.68–2.16) | |
| Not suppressed | 22 (44%) | 333 (49%) | |||
| Most recent CD4 | <500 cells/mm3 | 61 (80%) | 509 (60%) | 2.68 (1.54–4.97) | 2.19 (1.22–4.18) |
| ≥500 cells/mm3 | 15 (20%) | 336 (40%) | |||
| Clinic | Clinic 2 | 12 (16%) | 185 (22%) | 0.67 (0.34–1.23) | |
| Clinic 3 | 64 (84%) | 664 (78%) |
*viral load missing in 26 patients who started IPT and 163 patients not started on IPT
**most recent CD4 count missing in 4 patients not started on IPT
Self-reported barriers to IPT implementation among health care workers (HCWs).
| HCW (n = 25) | |
|---|---|
| Systematic screening for IPT-eligibility is difficult to implement | 1 (4%) |
| Current TB-screening is not sufficient to rule out TB | 7 (28%) |
| Counseling patients about IPT is difficult/time consuming | 7 (28%) |
| Patients not knowledgeable about IPT | 18 (72%) |
| Documentation of IPT activities is difficult/time consuming | 8 (32%) |
| Follow up of patients on IPT is difficult/time consuming | 4 (17%) |
| Motivating patients to adhere to IPT is difficult/time consuming | 3 (12%) |
| Not enough training in IPT guidelines | 0 (0%) |
| Not enough experience with prescribing IPT | 0 (0%) |
| IPT not part of routine practice | 1 (4%) |
| TST placement procedure is complex | 2 (10%) |
| HCW not comfortable placing TST | 0 (0%) |
| HCW has no time to perform TST | 18 (86%) |
| TST is limiting factor in decision to place patient on IPT | 0 (0%) |
| TST reading is time consuming | 3 (14%) |
| Difficult to motivate patients to return for TST reading | 15 (68%) |
$1 HCW excluded as didn´t follow up patients on IPT
¥2 HCWs excluded as they started after training
¶denominator for TST only 2 clinics (n = 22), TST not performed in clinic 2 (n = 3)
£2 HCWs excluded as they referred for TST
§1 missing answer
| WHO | South Africa [ | |
| IPT eligibility | All people living with HIV with negative symptom-based TB screening | All people living with HIV with negative symptom-based TB screening |
| TST provision | Use of TST where feasible. | Use of TST where available. |
| IPT duration | • TST positive or unknown: at least 36 months (as proxy for lifelong IPT), irrespective of ART | • TST positive: 36 months |
*in resource constrained settings with high TB prevalence